Paul Davis

[email protected]

Responsive - Making the most of the new banner ad formats

August 5, 2014

Page Layout Showing A Portrait Ad And Its Expansion Dimensions

Responsive - The Power of Landing Pages

August 5, 2014

2015 06 24 17 50 06 429 Inline

Responsive - 7 Deadly Sins of Landing Page Design

August 5, 2014

Responsive - 5 Short Videos to help you improve your eBroadcasts

August 5, 2014

Mismatched Goals

June 29, 2009

Lost in Translation...

February 5, 2008

2008 03 14 14 48 17 706

Agents of Change: The new wave of crawlers, spiders and bots

March 13, 2006

Defining your success

June 7, 2005

Defining your success

June 5, 2005

Rich Media: The power of being rich

March 30, 2005

Page 2 of 3

Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.

AI-driven cardiac PET attenuation correction shows promise

The algorithm could offer a “practical alternative in cardiac PET,” researchers noted.

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

Image-guided focal laser ablation effective for prostate cancer

Asco Thumb

ASCO: With help from AI, interventions boost lung cancer screening

2260299 Philips 01 Aunt Minnie Leadgen Newsletter Banner 300x250 Static

Philips Interactive Multimedia Reporting: Where Insight Meets Impact

David Vining Md Anderson Longitudinal Record Imr 2026

Radiologists estimate time savings with advanced radiology reports

SNMMI: Theranostic approach may treat PSMA-negative prostate cancer

By Amerigo Allegretto

A theranostic approach could help improve PET imaging for neuroendocrine prostate cancer care.

June 2, 2026

RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.

ASCO: Use of GLP-1 drugs linked to lower breast cancer cases

By Erik L. Ridley

A large retrospective study found sharply lower incidence of breast cancer among women who had received GLP-1 drugs.

June 2, 2026

SNMMI: CAIX-targeted PET tracer detects clear cell renal cell carcinoma

Researchers aim for "more precise molecular map" for kidney cancer.

June 1, 2026

A 68Ga-RCC78 PET scan (C) of a patient four years post-radical right nephrectomy. During follow-up, new nodules were detected in the left adrenal gland and kidney. CAIX-targeted scan clearly visualized metastatic lesions in the mediastinum, pancreas, adrenal gland, and kidney (SUVmax > 30), demonstrating the tracer's ability to maintain high tumor uptake despite significantly reduced abdominal background.

SNMMI: Low-cost absorbents clear over 90% of Lu-177 from wastewater

By Kate Madden Yee

An increase in the use of radionuclide therapy has added burden to wastewater management systems.

June 1, 2026

SNMMI: PET tracer that detects deep vein thrombosis wins Image of the Year

F-18 GP1 is derived from elarofiban and selectively binds to glycoprotein IIb/IIIa receptors on activated platelets.

June 1, 2026

(Left) F-18 GP1 PET/CT images from a 75-year-old woman show multiple blood clots in the deep veins of the left leg (from the thigh to the calf), as well as several clots in the right calf. Venous ultrasound confirms blood clots in left thigh, knee and calf veins. PET/CT also detects clots in both lungs, which are confirmed by contrast-enhanced CT image. (Right) 18F-GP1 PET/CT images from a 70-year-old woman show widespread blood clots throughout the body. In addition to clots in the deep veins of both legs and the arteries of both lungs (A), the scan also detected unexpected clots in several other areas, including blood vessels near the skull/head (B), spine (C), heart (D), and pelvis (E). Further evaluation revealed that the patient had antiphospholipid syndrome, an autoimmune condition that increases the risk of abnormal blood clot formation.

SNMMI: Novel radiotracer effectively images overactive adrenal glands

University of Michigan researchers report on first-in-human study of SOAT1-targeted nevanimibe C-11.

June 1, 2026

Static PET-CT image of patient with hypercortisolism taken at 60 minutes post-injection.

SNMMI: Mouaz Al-Mallah discusses cardiac PET

In this interview, Mouaz Al-Mallah, MD, discusses cardiac PET imaging, including new efforts to create more access for patients and the impact of new radiotracers.

June 1, 2026

Mouaz Al Mallah Thumb1

ASCO: Proton therapy, IMRT both work well for prostate cancer

By Erik L. Ridley

Both modalities yielded similar outcomes, according to preliminary results from a large, prospective trial.

June 1, 2026

SNMMI: Point-of-care PET system may guide interventional procedures

By Amerigo Allegretto

A portable, point-of-care PET system showed success in imaging organs and may be helpful in interventional guidance.

June 1, 2026

(a) Benchtop portable POC-PET prototype system. (b) Phantom imaging experiment setup. (c) Comparison of conventional full-data MLEM reconstruction with incremental OSEM reconstruction.

SNMMI: Brain-dedicated PET scanner cuts claustrophobia, boosts comfort

By Kate Madden Yee

The findings "support the use of brain-dedicated PET scanners as a patient-centered alternative," researchers wrote.

June 1, 2026

SNMMI: PET tracer detects CTE tau pathology in living patients

By Kate Madden Yee

Study findings suggest "a clinical role for PET in traumatic brain injury and sports- and military-related neurodegeneration."

May 31, 2026

Parametric maps obtained with SRTM2 (cerebellum grey matter as reference) for the group of healthy participants (top) and from one representative participant with suspected CTE (bottom). CTE: chronic traumatic encephalopathy.

SNMMI: SPECT/CT tracer shows promise in interstitial lung disease

Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.

May 31, 2026

Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.

Page 2 of 231